Site icon pharmaceutical daily

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H1
2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Chronic Inflammatory Demyelinating Polyneuropathy – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Chronic Inflammatory Demyelinating Polyneuropathy
(Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous
System) pipeline guide also reviews of key players involved in
therapeutic development for Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase I and Preclinical stages are 2, 3, 4
and 2 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous
System) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.

Scope:

Reasons to buy:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/997jz9/chronic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs

Exit mobile version